M E Schwartz

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. doi request reprint Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience
    Myron E Schwartz
    Department of Surgery, Mount Sinai School of Medicine, NewYork, NY 10029 6574, USA
    Recent Results Cancer Res 190:85-100. 2013
  2. pmc Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers
    Myron Schwartz
    Mount Sinai Liver Cancer Program, Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, New York, NY 10029, USA
    J Hepatol 49:581-8. 2008
  3. ncbi request reprint Comparison of a new fibrin sealant with standard topical hemostatic agents
    Myron Schwartz
    Department of Surgery, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Surg 139:1148-54. 2004
  4. ncbi request reprint Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?
    M E Schwartz
    Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY, USA
    Eur J Surg Oncol 34:256-62. 2008
  5. ncbi request reprint Safe transplantation of blood type A2 livers to blood type O recipients
    T M Fishbein
    Recanati Miller Transplantation Institute, Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 67:1071-3. 1999
  6. pmc One hundred nine living donor liver transplants in adults and children: a single-center experience
    C M Miller
    Recanati Miller Transplantation Institute, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York 10029, USA
    Ann Surg 234:301-11; discussion 311-2. 2001
  7. ncbi request reprint Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function
    S Emre
    Recanati Miller Transplantation Institute, The Mount Sinai Hospital of Mount Sinai NYU Health, One Gustave L Levy Pl, New York, NY 10029, USA
    Liver Transpl 7:220-5. 2001
  8. ncbi request reprint Long-term medical complications in patients surviving > or = 5 years after liver transplant
    P A Sheiner
    Recanati Miller Transplantation Institute, Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 69:781-9. 2000
  9. ncbi request reprint Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction
    P A Sheiner
    Division of Abdominal Organ Transplantation, The Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 64:1214-6. 1997
  10. ncbi request reprint Safety and risk of using pediatric donor livers in adult liver transplantation
    S Emre
    Recanati Miller Transplantation Institute, Mount Sinai Hospital of Mount Sinai NYU Health, New York, NY, USA
    Liver Transpl 7:41-7. 2001

Research Grants

Collaborators

Detail Information

Publications72

  1. doi request reprint Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience
    Myron E Schwartz
    Department of Surgery, Mount Sinai School of Medicine, NewYork, NY 10029 6574, USA
    Recent Results Cancer Res 190:85-100. 2013
    ..This chapter discusses various etiologies of noncirrhotic HCC and presents a large single-center experience that is compared to other Western series...
  2. pmc Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers
    Myron Schwartz
    Mount Sinai Liver Cancer Program, Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, New York, NY 10029, USA
    J Hepatol 49:581-8. 2008
    ..This study uses molecular data to identify a subgroup of patients who, despite having hepatocellular carcinoma beyond Milan criteria, have favorable outcomes...
  3. ncbi request reprint Comparison of a new fibrin sealant with standard topical hemostatic agents
    Myron Schwartz
    Department of Surgery, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Surg 139:1148-54. 2004
    ..Fibrin sealants represent an improvement over conventional topical hemostatic agents, because they contain components that actively form clot. However, most available agents contain nonhuman protein, which represents an immunologic risk...
  4. ncbi request reprint Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?
    M E Schwartz
    Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY, USA
    Eur J Surg Oncol 34:256-62. 2008
    ....
  5. ncbi request reprint Safe transplantation of blood type A2 livers to blood type O recipients
    T M Fishbein
    Recanati Miller Transplantation Institute, Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 67:1071-3. 1999
    ..This has led some to selectively offer A2 renal transplantation only for patients with low anti-A titers. Given the different clinical behavior of liver allografts to preformed antibody, we felt that such restriction was unnecessary...
  6. pmc One hundred nine living donor liver transplants in adults and children: a single-center experience
    C M Miller
    Recanati Miller Transplantation Institute, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York 10029, USA
    Ann Surg 234:301-11; discussion 311-2. 2001
    ..To summarize the evolution of a living donor liver transplant program and the authors' experience with 109 cases...
  7. ncbi request reprint Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function
    S Emre
    Recanati Miller Transplantation Institute, The Mount Sinai Hospital of Mount Sinai NYU Health, One Gustave L Levy Pl, New York, NY 10029, USA
    Liver Transpl 7:220-5. 2001
    ..In patients with impaired renal function before LT, daclizumab-based initial immunosuppression can be used safely to reduce the risk for infection and need for dialysis post-LT, with improved long-term graft and patient survival...
  8. ncbi request reprint Long-term medical complications in patients surviving > or = 5 years after liver transplant
    P A Sheiner
    Recanati Miller Transplantation Institute, Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 69:781-9. 2000
    ..We sought to analyze long-term complications in liver recipients surviving > or =5 years after transplant, to assess their medical condition and to compare findings to the general population...
  9. ncbi request reprint Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction
    P A Sheiner
    Division of Abdominal Organ Transplantation, The Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 64:1214-6. 1997
    ..We evaluated the utility of CD3 cell counts for monitoring OKT3 induction immunosuppression and for predicting early rejection in liver recipients...
  10. ncbi request reprint Safety and risk of using pediatric donor livers in adult liver transplantation
    S Emre
    Recanati Miller Transplantation Institute, Mount Sinai Hospital of Mount Sinai NYU Health, New York, NY, USA
    Liver Transpl 7:41-7. 2001
    ..The outcome of small-for-size grafts is more likely to be adversely affected by longer WITs and CITs. The safe limit of graft volume appeared to be a DLW/ERLW of 0. 4 or greater...
  11. ncbi request reprint Selective revascularization of hepatic artery thromboses after liver transplantation improves patient and graft survival
    P A Sheiner
    Department of Surgery, The Mount Sinai Medical Center, New York, New York 10029, USA
    Transplantation 64:1295-9. 1997
    ..Hepatic artery thrombosis (HAT) can be a devastating complication of orthotopic liver transplantation (OLT), but early diagnosis may allow successful revascularization and graft salvage...
  12. doi request reprint Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation
    M T Killackey
    Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, USA
    Transplant Proc 40:1504-10. 2008
    ....
  13. ncbi request reprint Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients
    S Emre
    Recanati Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY 10029, USA
    Transpl Int 13:73-8. 2000
    ..When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome...
  14. ncbi request reprint Orthotopic liver transplantation for Wilson's disease: a single-center experience
    S Emre
    the Recanati Miller Transplant Institute, Department of Medicine, The Mount Sinai School of Medicine, New York, NY, USA
    Transplantation 72:1232-6. 2001
    ..The aim of this study is to review our experience with OLT for patients with Wilson's disease...
  15. ncbi request reprint Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease
    M Ben-Haim
    The Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, New York, NY, USA
    Liver Transpl 7:948-53. 2001
    ..6% can be used safely in patients without cirrhosis or in patients with Child's class A. Transplant recipients with Child's class B or C require a GRWR greater than 0.85% to avoid small-for-size syndrome and related complications...
  16. pmc Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels
    P A Sheiner
    The Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mediators Inflamm 10:37-41. 2001
    ..CONCLUSIONS: These results suggest that while these cytokines are associated with post-transplant recurrence of hepatitis C, their production may be altered by additional factors...
  17. doi request reprint Outcome for patients treated with laparoscopic versus open resection of hepatocellular carcinoma: case-matched analysis
    U Sarpel
    Department of Surgery, New York University Medical Center, New York, USA
    Ann Surg Oncol 16:1572-7. 2009
    ..This is a case-matched analysis of patients undergoing laparoscopic versus open hepatectomy for hepatocellular carcinoma (HCC), with specific regard to margin status and survival...
  18. doi request reprint The Mount Sinai experience with orthotopic liver transplantation for benign tumors: brief report and literature review: case reports
    M E Schwartz
    Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY, USA
    Transplant Proc 40:1759-62. 2008
    ..In this report, we present our experience with OLT for benign liver tumors, commenting on relevant published studies...
  19. doi request reprint Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective
    Fotini Manizate
    Department of Surgery, Division of Surgical Oncology, The Mount Sinai Medical Center, 5 East 98th Street, 12th Floor, Box 1259, New York, NY 10029, USA
    J Hepatobiliary Pancreat Sci 17:385-8. 2010
    ..Preoperative portal vein embolization is a strategy that can evoke regeneration in anticipation of surgery, serving as a "stress test" of the liver's regenerative capacity...
  20. ncbi request reprint Liver transplantation in patients with hepatocellular carcinoma
    Myron Schwartz
    Adult Liver Transplantation and Hepatobiliary Surgery, The Mount Sinai School of Medicine, New York, New York, USA
    Liver Transpl 10:S81-5. 2004
    ..Finally, the impact of viral hepatitis and of immunosuppression on transplant outcome are discussed...
  21. ncbi request reprint A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
    Gastroenterology 131:1758-67. 2006
    ..Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC)...
  22. ncbi request reprint Treatment strategies for hepatocellular carcinoma in cirrhosis
    W Scott Helton
    Department of Surgery, University of Illinois, Chicago, IL, USA
    J Gastrointest Surg 7:401-11. 2003
  23. doi request reprint Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma
    Igor Dvorchik
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 3236, USA
    Liver Transpl 14:443-50. 2008
    ..Incorporation of these molecular markers of tumor progression could help resolve the ongoing conundrum of organ allocation for patients with HCC...
  24. ncbi request reprint Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial
    M W Sung
    Division of Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mol Ther 4:182-91. 2001
    ..0x10(13) virus particles per patient, and can provide the basis for future clinical trials involving intratumoral adenoviral vector injection...
  25. ncbi request reprint Noninvasive preoperative evaluation of biliary anatomy in right-lobe living donors with mangafodipir trisodium-enhanced MR cholangiography
    J Goldman
    Department of Radiology, Mount Sinai Hospital, New York, New York 10029, USA
    Transplant Proc 35:1421-2. 2003
    ..Volumetric magnetic resonance cholangiography (MRCP) using Mangafodipir trisodium (Mn-DPDP) contrast has been recently proposed to evaluate the biliary anatomy of living donor candidates...
  26. ncbi request reprint Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma
    Sigal Kremer-Tal
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 40:1047-52. 2004
    ..In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors...
  27. ncbi request reprint Liver transplantation for hepatocellular carcinoma
    Myron Schwartz
    Department of Adult Liver Transplantation and Hepatobiliary Surgery, The Mount Sinai School of Medicine, 1 Gustave Levy Pl, Box 1104, New York, New York 10029, USA
    Gastroenterology 127:S268-76. 2004
    ..In considering liver transplantation, the impact of the underlying liver disease is an important consideration; recurrent hepatitis C after transplant lowers patient survival independent of tumor recurrence...
  28. doi request reprint Liver functional reserve estimation: state of the art and relevance to local treatments
    Fotini Manizate
    Department of Surgery, Division of Surgical Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    Oncology 78:131-4. 2010
    ..Preoperative portal vein embolization is a strategy that can evoke 'regeneration' in anticipation of surgery, serving as a 'stress test' of the liver's regenerative capacity...
  29. ncbi request reprint How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?
    Myron Schwartz
    Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, USA
    J Hepatol 43:584-9. 2005
  30. ncbi request reprint Strategies for the management of hepatocellular carcinoma
    Myron Schwartz
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Oncol 4:424-32. 2007
    ..There is a need for more effective adjuvant therapies after resection and liver transplantation; newer antiangiogenic agents offer hope for improved outcomes in the future...
  31. ncbi request reprint Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Divisions of Liver Disease and Recanati Miller Transplantation Institute, Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA
    Semin Liver Dis 26:248-53. 2006
    ..Only a few small studies with heterogeneous target populations and treatments applied are available. The results of these studies are inconsistent and do not provide compelling evidence to accept down-staging as a standard of care...
  32. ncbi request reprint De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature
    Anca Croitoru
    The Lillian and Henry M Stratton Hans Popper Department of Pathology, The Mount Sinai Medical Center, One Gustave L Levy Place, New York, New York 10029, USA
    Dig Dis Sci 51:1780-2. 2006
  33. ncbi request reprint Liver transplantation: the preferred treatment for early hepatocellular carcinoma in the setting of cirrhosis?
    Myron Schwartz
    Department of Surgery, New York University, 1 Gustave L Levy Place, Box 1104, New York, New York 10029, United States
    Ann Surg Oncol 14:548-52. 2007
  34. ncbi request reprint Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
    Elisa Wurmbach
    Mount Sinai Liver Cancer Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 45:938-47. 2007
    ..CONCLUSION: These findings provide a comprehensive molecular portrait of genomic changes in progressive HCV-related HCC...
  35. ncbi request reprint Liver transplantation for neuroendocrine tumors
    Sander Florman
    Recanati Miller Transplantation Institute, The Mount Sinai School of Medicine, New York, New York, USA
    J Gastrointest Surg 8:208-12. 2004
    ..Of the three patients surviving more than 5 years, only one was disease free. In carefully selected patients with metastatic NETs, liver transplantation may be an appropriate option...
  36. pmc Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma
    Q Wang
    Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA
    Br J Cancer 109:573-81. 2013
    ..Established cirrhosis, as defined histologically by Ishak stage 6, is an independent predictor of poor overall and recurrence-free survival among these patients. ..
  37. ncbi request reprint A simple new formula to assess liver weight
    T Yoshizumi
    Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Transplant Proc 35:1415-20. 2003
    ..We sought to establish a simple, reliable formula for accurate prediction of liver volume...
  38. pmc Pivotal role of mTOR signaling in hepatocellular carcinoma
    Augusto Villanueva
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Gastroenterology 135:1972-83, 1983.e1-11. 2008
    ..We evaluated mTOR signaling in human HCC, as well as the antitumoral effect of a dual-level blockade of the mTOR pathway...
  39. ncbi request reprint Hand-assisted laparoscopic donor hepatectomy for living related transplantation in the porcine model
    Marina S Kurian
    Division of Laparoscopic Surgery, Department of Surgery, Mount Sinai School of Medicine, 5 East 98th Street, New York, NY 10029, USA
    Surg Laparosc Endosc Percutan Tech 12:232-7. 2002
    ..The resected liver had minimal warm ischemia time and microscopic changes, which led us to believe that the organ was suitable for transplantation. We believe that this long-term study establishes the feasibility of this procedure...
  40. ncbi request reprint Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials
    Jonathan D Schwartz
    Mount Sinai School of Medicine, Medical Oncology, New York, NY 10029, USA
    Lancet Oncol 3:593-603. 2002
    ..Other adjuvant modalities (mostly tested in small, preliminary settings) may confer benefit after potentially curative resection of HCC...
  41. pmc Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
    ..We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models...
  42. pmc Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation
    Sigal Kremer-Tal
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    J Hepatol 46:645-54. 2007
    ..Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation...
  43. ncbi request reprint Unresectable squamous cell carcinoma of donor origin treated with immunosuppression withdrawal and liver retransplantation
    Sander Florman
    The Recanati Miller Transplantation Institute, New York, NY, USA
    Am J Transplant 4:278-82. 2004
    ..More than 2 years later she remains disease-free with complete pathological remission. This is the only reported case of squamous cell carcinoma of donor origin arising in a transplanted liver...
  44. ncbi request reprint Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression
    Jonathan D Schwartz
    Hematology Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 10:718-27. 2005
    ..Systemic therapy is minimally effective in HCC and tumor angiogenesis is a potential therapeutic target...
  45. ncbi request reprint Candidate selection criteria for living donor liver transplantation
    Myron Schwartz
    Recanati Miller Transplantation Institute, Box 1104, Mount Sinai School of Medicine, 1 East 100th Street, New York, NY 10029 6574, USA
    Mt Sinai J Med 70:171-3. 2003
    ..The risk to the living donor, an order of magnitude higher than that for kidney donation, raises different ethical concerns related to autonomy, what constitutes an acceptable risk-benefit equation, and who is to decide...
  46. doi request reprint Trefoil factor-3 expression in human colon cancer liver metastasis
    Mark Babyatsky
    The Dr Henry D Janowitz Division of Gastroenterology, Department of Medicine, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1069, New York, NY 10029 6574, USA
    Clin Exp Metastasis 26:143-51. 2009
    ..These results provide further evidence that TFF3 contributes to the malignant behavior of colon cancer cells. These observations may have relevance for designing new diagnostic and treatment approaches to colorectal cancer...
  47. ncbi request reprint Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor
    Charles Miller
    Recanati Miller Transplantation Institute, New York, NY, USA
    Liver Transpl 10:1315-9. 2004
    ..In conclusion, herein we present the facts and discuss this extraordinary example of florid clostridial infection and toxin-mediated shock. It was completely unexpected and probably unpreventable, and its cause was almost inconceivable...
  48. ncbi request reprint Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation
    Adeyemi Lawal
    Department of Medicine and Division of Liver Diseases, The Mount Sinai Medical Center, New York, NY, USA
    Am J Transplant 4:1805-9. 2004
    ..Influenza virus vaccination is not associated with allograft rejection or ALT flares in liver transplant recipients...
  49. ncbi request reprint The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation
    Sander Florman
    The Recanti Miller Transplantation Institute, The Mount Sinai School of Medicine, New York, USA
    Clin Transplant 18:152-5. 2004
    ..4% while for patients without late ACR (n = 488) it is 82.0% (p = ns). Patients remain at risk for ACR even after 1000 d post-transplant, particularly those with PSC...
  50. doi request reprint Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience
    Manousos M Konstadoulakis
    Recanati Miller Transplantation Institute, Hippocration Hospital of Athens, Athens Medical School, Athens, Greece
    Am J Surg 196:160-9. 2008
    ..The current study presents our experience with resectional surgery for patients with hilar cholangiocarcinoma (HC)...
  51. ncbi request reprint Biliary complications in 96 consecutive right lobe living donor transplant recipients
    Gabriel E Gondolesi
    Recanati Miller Transplantation Institute, Mount Sinai Hospital, Box 1104, One Gustave L Levy Place, New York, NY 10029, USA
    Transplantation 77:1842-8. 2004
    ..Biliary reconstruction represents one of the most challenging parts of right lobe (RL) living donor liver transplantations (LDLTs). Different causes, surgical techniques, and treatments have been suggested but are incompletely defined...
  52. ncbi request reprint Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection
    Luis Munoz
    The Mount Sinai School of Medicine, Recanati Miller Transplantation Institute, New York, NY, USA
    J Hepatobiliary Pancreat Surg 9:237-41. 2002
    ..Portal bifurcation involvement is often thought to contraindicate resection. We reviewed our experience with aggressive surgical management in 28 patients with hilar cholangiocarcinoma...
  53. ncbi request reprint Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors
    Thomas D Schiano
    The Recanati Miller Transplantation Institute, The Mount Sinai Hospital, New York, NY, USA
    Hepatology 42:1420-8. 2005
    ..The trend toward a greater initial viral load decrease in patients with LD grafts and the significantly sharper increase suggest that the liver plays a predominant role in both HCV clearance and replication...
  54. ncbi request reprint Anatomic variations in right liver living donors
    Giovanni Varotti
    Recanati Miller Transplantation Institute, Mount Sinai Hospital, One Gustave L Levy Place, New York, NY 10029, USA
    J Am Coll Surg 198:577-82. 2004
    ..Anatomic knowledge is crucial in right liver living donor transplantation...
  55. ncbi request reprint An integrated approach to intestinal failure: results of a new program with total parenteral nutrition, bowel rehabilitation, and transplantation
    Thomas M Fishbein
    Recanati Miller Transplantation Institute, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Gastrointest Surg 6:554-62. 2002
    ....
  56. ncbi request reprint Quality of life after lobectomy for adult liver transplantation
    Leona Kim-Schluger
    Recanati Miller Transplantation Institute, and Department of Psychiatry, Mount Sinai Hospital, New York, New York 10029, USA
    Transplantation 73:1593-7. 2002
    ..Adult-to-adult living donor liver transplants are being increasingly performed. Although considerable data are available on the quality of life after kidney donation, there is little comparable information on liver donors...
  57. ncbi request reprint Hepatocellular carcinoma: a prime indication for living donor liver transplantation
    Gabriel Gondolesi
    Recanati Miller Transplantation Institute, Mount Sinai Hospital, New York, NY 10029, USA
    J Gastrointest Surg 6:102-7. 2002
    ....
  58. pmc Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters
    Sasan Roayaie
    Recanati Miller Transplantation Institute, New York, New York, USA
    Ann Surg 235:533-9. 2002
    ..To determine the long-term results of liver transplantation for hepatocellular carcinoma (HCC) measuring 5 cm or larger treated in a multimodality adjuvant protocol...
  59. doi request reprint Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome
    Manousos M Konstadoulakis
    Recanati Miller Transplantation Institute, Mount Sinai Medical Center, New York, NY, USA
    Surgery 143:366-74. 2008
    ..In the current report, we present our experience with the surgical management of ICC, analyze operative results, and investigate prognostic factors in resected patients...
  60. ncbi request reprint Venous hemodynamics in living donor right lobe liver transplantation
    Gabriel E Gondolesi
    The Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Liver Transpl 8:809-13. 2002
    ..Evaluation of hepatic and portal venous flow is a relatively easy skill to acquire. Intraoperative ultrasound may enable the surgeon to predict graft dysfunction and possibly, may be used to implement pre-emptive therapies...
  61. pmc Liver transplantation for hepatocellular carcinoma
    Vincenzo Mazzaferro
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 15:1001-7. 2008
    ....
  62. pmc Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria
    Gabriel E Gondolesi
    Recanati Miller Transplantation Institutes, The Mount Sinai Hospital, New York, NY 10029, USA
    Ann Surg 239:142-9. 2004
    ..LDLT allows timely transplantation in patients with early or with large HCC...
  63. ncbi request reprint Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis
    Sasan Roayaie
    Recanati Miller Transplantation Institute, Department of Medicine, Mount Sinai Medical Center, Mount Sinai NYU Health System, New York, NY 10029, USA
    Liver Transpl 10:534-40. 2004
    ..Nonetheless, some patients with recurrence can be expected to live for a considerable period of time. Recurrent disease should be treated surgically when possible, because surgery is independently associated with longer survival...
  64. ncbi request reprint Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis
    Giovanni Varotti
    Recanati Miller Transplantation Institute, The Mount Sinai Hospital, New York, NY, USA
    J Am Coll Surg 197:765-9. 2003
    ..Approximately 20% to 30% of cholangiocarcinomas are localized in the distal bile duct. Pancreatoduodenectomy is the curative therapy for cholangiocarcinomas in this location...
  65. ncbi request reprint Liver transplantation for liver rupture due to light chain deposition disease: a case report
    Anca G Croitoru
    Department of Pathology, University of Alabama at Birmingham, USA
    Semin Liver Dis 26:298-303. 2006
    ..In this case, the deposits were composed of unbranched fibrils, which measured 12 to 20 nm in width, did not possess a hollow core, and were arranged randomly rather than in structured arrays...
  66. ncbi request reprint Results of retransplantation for recurrent hepatitis C
    Sasan Roayaie
    Recanati Miller Transplantation Institute, Mount Sinai Hospital of Mount Sinai NYU Health, New York, NY 10029, USA
    Hepatology 38:1428-36. 2003
    ..Candidates for retransplantation with a preoperative PT less than 16 seconds and those receiving grafts from donors younger than 60 years can expect a significantly longer median survival after retransplantation...
  67. ncbi request reprint Invasive colloid carcinoma arising from intraductal papillary neoplasm in a 50-year-old woman with primary sclerosing cholangitis
    Moueen Bu-Ghanim
    The Lillian and Henry M Stratton Hans Popper Department of Pathology, Mount Sinai Medical Center, New York, New York 10001, USA
    Semin Liver Dis 24:209-13. 2004
  68. ncbi request reprint Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome
    Michal Carmiel-Haggai
    Recanati Miller Transplantation Institute, Mount Sinai Hospital, The Mount Sinai School of Medicine, PO Box 1504, New York, NY 10029 6574, USA
    Liver Transpl 11:1567-73. 2005
    ..Patients experiencing early graft failure due to accelerated forms of HCV should not be denied re-LT with the expectation that a similar disease course will occur after re-LT...
  69. ncbi request reprint Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients
    Lawrence U Liu
    Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, NY 10029, USA
    Transplantation 80:1072-80. 2005
    ..The aims of this study were to compare the incidence of ACR between recipients of live- and deceased-donor liver transplants, and to note any differences in ACR among related and unrelated living-donor recipients...
  70. ncbi request reprint Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis
    Richard K Sterling
    Virginia Commonwealth University Health Systems, Richmond, Virginia, USA
    Am J Gastroenterol 102:2196-205. 2007
    ..The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total AFP in North American patients...
  71. ncbi request reprint Syngeneic living-donor liver transplantation without the use of immunosuppression
    Lawrence U Liu
    The Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, New York 10029, USA
    Gastroenterology 123:1341-5. 2002
    ..Although HLA matched genotypically, there may be differences in anatomy between donor and recipient. Mild liver chemistry test abnormalities may occur after transplant despite the absence of immunosuppression...
  72. ncbi request reprint Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease
    Anil S Paramesh
    The Recanat Miller Transplantation Institute, The Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Clin Transplant 18:94-9. 2004
    ..The aim of this study was to determine factors that might predict the development of end stage renal disease (ESRD) in patients who had ARF after OLT...

Research Grants1

  1. Systematic Integration POR into Clinical Pathway of HCC
    Myron Schwartz; Fiscal Year: 2006
    ..This program provides a truly remarkable opportunity to make meaningful progress in understanding, preventing and treating HCC, while in the process providing fertile training ground for young physician-scientists. ..